The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial rev...

Full description

Bibliographic Details
Main Authors: Anastasia Lanzi, F. A. Sinicrope, A. B. Benson, Jérôme Galon
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
immunoscore
tumor microenvironment
cancer classification
prognosis
immunity
phase 3 trial
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1796003

Internet

http://dx.doi.org/10.1080/2162402X.2020.1796003

Similar Items